What's New

December

Invizyne Technologies, Inc. (PDF) (December 1, 2025)

Blue Rabbit Veterinary LLC (PDF) (December 1, 2025)

Benuvia Operations, LLC (PDF) (December 1, 2025)

November

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026 (PDF) (November 28, 2025)

Groff NA Hemplex LLC (PDF) (November 26, 2025)

Halo Pharmaceutical Inc. (PDF) (November 26, 2025)

Siegfried Grafton, Inc. (PDF) (November 26, 2025)

Caligor Coghlan Pharma Services (PDF) (November 26, 2025)

Noramco (PDF) (November 26, 2025)

NSI Lab Solutions, LLC (PDF) (November 26, 2025)

Irvine Labs, Inc. (PDF) (November 26, 2025)

Noramco (PDF) (November 26, 2025)

Organic Standards Solutions International, LLC (PDF) (November 26, 2025)

Siegfried Grafton, Inc. (PDF) (November 26, 2025)

Eli-Elsohly Laboratories (PDF) (November 26, 2025)

VHG Labs DBA LGC Standards (PDF) (November 26, 2025)

Benuvia Operations, LLC (PDF) (November 26, 2025)

Organix Chemistry Solutions, LLC (PDF) (November 26, 2025)

National Center for Natural Products Research (PDF) (November 26, 2025)

Fisher Clinical Services, Inc. (PDF) (November 26, 2025)

Cayman Chemical Company (PDF) (November 26, 2025)

Irvine Labs Inc. (PDF) (November 26, 2025)

Irvine Labs, Inc. (PDF) (November 26, 2025)

30-Day Notice: DEA Voluntary Wellness Program Healthcare Provider Clearance (PDF) (November 24, 2025)

60-Day Notice: Drug Use Statement (PDF) (November 24, 2025)

30-Day Notice: Report of Mail Order Transactions (PDF) (November 18, 2025)

Final Rule: Placement of 4-Chloromethcathinone in Schedule I (PDF) (November 17, 2025)

October

Tracy Amerson-Rivers, A.P.R.N.; Decision and Order (PDF) (October 30, 2025)

Antony Vanbang, M.D.; Decision and Order (PDF) (October 30, 2025)

Dawn Evert, N.P.; Decision and Order (PDF) (October 30, 2025)

Pharmacy Place, Llc; Decision and Order (PDF) (October 30, 2025)

Lawrence Michael Willis, D.D.S.; Decision and Order (PDF) (October 30, 2025)

Mert Kivanc, D.O.; Decision and Order (PDF) (October 21, 2025)

MCRGC, LLC; Decision and Order (PDF) (October 21, 2025)

Enyibuaku Uzoaga, M.D.; Decision and Order (PDF) (October 21, 2025)

Hil Rizvi, M.D.; Decision and Order (PDF) (October 21, 2025)

Abolghasem Rezaei, M.D.; Decision and Order (PDF) (October 20, 2025)

Ali Elhorr, M.D.; Decision and Order (PDF) (October 20, 2025)

Chantal F. Nouvellon, D.O.; Decision and Order (PDF) (October 20, 2025)

James Orrington, II, D.D.S.; Decision and Order (PDF) (October 20, 2025)

Grace S. Joanita, N.P.; Decision and Order (PDF) (October 17, 2025)

Hovic Pharmacy; Decision and Order (PDF) (October 17, 2025)

Shannon Wagner, D.O.; Decision and Order (PDF) (October 17, 2025)

David S. Pecora, P.A.; Decision and Order (PDF) (October 17, 2025)

Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I (PDF) (October 15, 2025)

Final Order: Adjustment to the Aggregate Production Quota for d-Amphetamine (For Sale) and Methylphenidate (For Sale) for 2025 Pursuant to 21 U.S.C. 826(h) (PDF) (October 2, 2025)

Hollywood Medical Rehabilitation Care, Inc.; Decision and Order (PDF) (October 2, 2025)

Cargill, Incorporated (PDF) (October 2, 2025)

Proposed Rule: Designation of P2P Methyl Glycidic Acid as a List I Chemical (PDF) (October 2, 2025)

Proposed Rule: Placement of MDMB-4en-PINACA in Schedule I (PDF) (October 2, 2025)

Final Rule: Requiring Online Submission of Applications for and Renewals of DEA Registration: Technical Correction (PDF) (October 2, 2025)

Final Rule: Specific Listing for 1-boc-4-piperidone, a Currently Controlled List I Chemical (PDF) (October 2, 2025)

Final Rule: Controlled Substances Ordering System (CSOS) Modernization (PDF) (October 2, 2025)

September

Jody Adams, N.P.; Decision and Order (PDF) (September 30, 2025)

Denise Henderson, M.D.; Decision and Order (PDF) (September 30, 2025)

David Payne, M.D.; Decision and Order (PDF) (September 30, 2025)

Henry Emery, M.D.; Decision and Order (PDF) (September 30, 2025)

Groff NA Hemplex LLC (PDF) (September 30, 2025)

Rachel Kientcha-Tita, M.D.; Decision and Order (PDF) (September 23, 2025)

Immacula Michel, M.D.; Decision and Order (PDF) (September 23, 2025)

Groff Health Inc. (PDF) (September 22, 2025)

Final Order: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2025 Pursuant to 21 U.S.C. 826(h) (PDF) (September 19, 2025)

Eric Andersen, D.D.S.; Decision and Order (PDF) (September 19, 2025)

Haroon Hameed, M.D.; Decision and Order (PDF) (September 19, 2025)

Final Rule: Placement of Seven Specific Fentanyl-Related Substances in Schedule I (PDF) (September 18, 2025)

Catalent Greenville, Inc. (PDF) (September 16, 2025)

Fisher Clinical Services, Inc. (PDF) (September 12, 2025)

Fresenius Kabi USA, LLC (PDF) (September 12, 2025)

Cambridge Isotope Laboratories, Inc. (PDF) (September 12, 2025)

Cambridge Isotope Laboratories, Inc. (PDF) (September 12, 2025)

Catalent Pharma Solutions, LLC (PDF) (September 12, 2025)

Chanelle D. Remien, DVM; Decision and Order (PDF) (September 11, 2025)

Biopharmaceutical Research Company (PDF) (September 11, 2025)

30-Day Notice (Extension): Application for Registration Under Domestic Chemical Diversion Control Act of 1993 (DEA Form 510); Renewal Application for Registration Under Domestic Chemical Diversion Control Act of 1993 (DEA Form 510a) (PDF) (September 10, 2025)

30-Day Notice (Extension): Application for Registration—DEA Form 363, Application for Registration Renewal—DEA Form 363a (PDF) (September 10, 2025)

30-Day Notice (Extension): Annual Reporting for Manufacturers of Listed Chemicals (PDF) (September 10, 2025)

60-Day Notice: Reporting and Recordkeeping for Digital Certificates—Form 251 (PDF) (September 9, 2025)

VA Cooperative Studies Program (PDF) (September 8, 2025)

60-Day Notice (Extension): Report of Mail Order Transactions (PDF) (September 5, 2025)

July

Taha Dias, M.D.; Decision and Order (PDF) (July 25, 2025)

Proposed Rule: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act (PDF) (July 25, 2025)

Extension of Temporary Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act (PDF) (July 25, 2025)

Thomas Draschil, M.D.; Decision and Order (PDF) (July 22, 2025)

AndersonBrecon, Inc. DBA PCI Pharma Services (PDF) (July 17, 2025)

AMPAC Fine Chemicals LLC (PDF) (July 17, 2025)

Curia Missouri Inc. (PDF) (July 17, 2025)

Curia New York, Inc. (PDF) (July 17, 2025)

Cerilliant Corporation (PDF) (July 17, 2025)

Cerilliant Corporation (PDF) (July 17, 2025)

Benson Sergiles, P.A.; Decision and Order (PDF) (July 16, 2025)

Sasha Melissa Ikramelahai; Decision and Order (PDF) (July 16, 2025)

Osric Malone Prioleau, N.P.; Decision And Order (PDF) (July 16, 2025)

Diana Clouthier, N.P.; Decision and Order (PDF) (July 16, 2025)

Elias Garcia Garcia, P.A.; Decision and Order (PDF) (July 14, 2025)

JYA LLC d/b/a Webb's Square Pharmacy; Decision and Order (PDF) (July 14, 2025)

Michael Bouknight; Decision and Order (PDF) (July 14, 2025)

Just Here II Pharmacy; Decision and Order (PDF) (July 14, 2025)

John Hanley, P.A.; Decision and Order (PDF) (July 9, 2025)

Andrew Jones, M.D.; Decision and Order (PDF) (July 9, 2025)

Hayriye Gok, M.D.; Decision and Order (PDF) (July 9, 2025)

William Washington, M.D.; Decision and Order (PDF) (July 8, 2025)

Tanya Newlove, N.P.; Decision and Order (PDF) (July 8, 2025)

Mark Agresti, M.D.; Decision and Order (PDF) (July 8, 2025)

Loretta Clement, M.D.; Decision and Order (PDF) (July 7, 2025)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (July 1, 2025)

 

  • REGISTRATION
  • REPORTING
  • RESOURCES
  • CONTACT US
  • PRIVACY NOTICE
  • GET EMAIL UPDATES